Cargando…

Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan

Human cells and tissue products belong to a relatively new class of medical products. Therefore, limited information is available on the classification and premarket evaluation of human cells and tissue products in the United States (US), the European Union (EU), and Japan. In this study, the defini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yano, Kazuo, Watanabe, Natsumi, Tsuyuki, Kenichiro, Ikawa, Taisuke, Kasanuki, Hiroshi, Yamato, Masayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japanese Society for Regenerative Medicine 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581762/ https://www.ncbi.nlm.nih.gov/pubmed/31589662 http://dx.doi.org/10.1016/j.reth.2014.10.001

Ejemplares similares

Compassionate use of drugs and medical devices in the United States, the European Union and Japan
por: Tsuyuki, Kenichiro, et al.
Publicado: (2016)

Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera
por: Watanabe, Natsumi, et al.
Publicado: (2015)

Non-clinical assessment design of autologous chondrocyte implantation products
por: Ikawa, Taisuke, et al.
Publicado: (2015)

Bayesian statistics and clinical trial designs for human cells and tissue products for regulatory approval
por: Jokura, Yoji, et al.
Publicado: (2016)

Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union
por: Jokura, Yoji, et al.
Publicado: (2017)

Expedited approval system for regenerative medicine products – Is it unusual?
por: Yano, Kazuo, et al.
Publicado: (2016)

PRP therapy classification
por: Yamato, Masayuki, et al.
Publicado: (2015)

Predictors of orphan drug approval in the European Union
por: Heemstra, Harald E., et al.
Publicado: (2008)

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
por: Hwang, Thomas J., et al.
Publicado: (2022)

Approval and Certification of Ophthalmic AI Devices in the European Union
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell‐ and tissue‐based products regulatory policy in the United States?
por: Yano, Kazuo, et al.
Publicado: (2018)

Cell-based medicinal products approved in the European Union: current evidence and perspectives
por: Bellino, Stefania, et al.
Publicado: (2023)

A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020
por: Teixeira, Maria Manuel, et al.
Publicado: (2022)

Navigating the maze of requirements for obtaining approval of non-interventional studies (NIS) in the European Union
por: Ramirez, Isabelle
Publicado: (2015)

Engineered Microorganisms for the Production of Food Additives Approved by the European Union—A Systematic Analysis
por: Kallscheuer, Nicolai
Publicado: (2018)

Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non‐orphan, Non‐oncology Drugs in the European Union and United States from 2012−2016
por: Morant, Anne Vinther, et al.
Publicado: (2019)

Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan
por: Maeda, Hideki, et al.
Publicado: (2022)

An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004–2018)
por: Konwar, Mahanjit, et al.
Publicado: (2021)

COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients
por: Bellino, Stefania
Publicado: (2022)

Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study
por: Hwang, Thomas J, et al.
Publicado: (2016)

Compassionate use and hospital exemption for regenerative medicine: Something wrong to apply the program for patients in a real world
por: Yano, Kazuo, et al.
Publicado: (2018)

Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union
por: Pellegrini, Graziella, et al.
Publicado: (2017)

Consumers' acceptance of the first novel insect food approved in the European Union: Predictors of yellow mealworm chips consumption
por: Petrescu‐Mag, Ruxandra Malina, et al.
Publicado: (2022)

Lifecycle management of orphan drugs approved in Japan
por: Seki, Kiyoshi, et al.
Publicado: (2022)

A Regulatory Take on Cannabis and Cannabinoids for Medicinal use in the European Union
por: Lipnik-Štangelj, Metoda, et al.
Publicado: (2020)

Recent Least Burdensome Approach for the Approval of Innovative Medical Devices in Japan -Regulatory Approval Review of an Everolimus-eluting Bioresorbable Scaffold-
por: Konishi, Akihide, et al.
Publicado: (2020)

Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States
por: Lee, Mijin, et al.
Publicado: (2023)

The European Health Union and the protection of public health in the European Union: Is the European Union prepared for future cross-border health threats?
por: Seitz, Claudia
Publicado: (2023)

COVID‐19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union
por: de Jong, Amos Jochanan, et al.
Publicado: (2021)

Digitizing the Informed Consent Process: A Review of the Regulatory Landscape in the European Union
por: De Sutter, Evelien, et al.
Publicado: (2022)

Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union
por: García-Arieta, Alfredo, et al.
Publicado: (2023)

The European Union and the Regions /
Publicado: (1995)

Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis
por: Tanaka, Mototsugu, et al.
Publicado: (2020)

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit
por: Mulder, J., et al.
Publicado: (2023)

Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional study
por: Shimazawa, Rumiko, et al.
Publicado: (2017)

Analysis of the Regulatory, Legal, and Medical Conditions for the Prescription of Mobile Health Applications in the United States, The European Union, and France
por: Hassanaly, Parina, et al.
Publicado: (2021)

Comparing cancer drug approval systems in the United States and Japan
por: Kaneda, Yudai, et al.
Publicado: (2023)

REGULATORY OR REGULATING PUBLICS? THE EUROPEAN UNION'S REGULATION OF EMERGING HEALTH TECHNOLOGIES AND CITIZEN PARTICIPATION
por: Flear, Mark L., et al.
Publicado: (2013)

Pesticides and public health: an analysis of the regulatory approach to assessing the carcinogenicity of glyphosate in the European Union
por: Clausing, Peter, et al.
Publicado: (2018)

Towards a future regulatory framework for chemicals in the European Union – Chemicals 2.0
por: Berggren, Elisabet, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cih71kj6ol8r2hrsrevqkl79ga